Vitamin D attenuates proteinuria by inhibition of heparanase expression in the podocyte

Journal of Pathology

Volumn 237, Issue 4, 2015, Pages 472-481

  Garsen, Marjolein ^a   Sonneveld, Ramon ^a   Rops, Angelique Lwmm ^a   Huntink, Suzanne ^a   Van Kuppevelt, Toin H ^b   Rabelink, Ton J ^c   Hoenderop, Joost G ^b   Berden, Jo Hm ^a   Nijenhuis, Tom ^a   Van Der Vlag, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

heparanase; podocyte; proteinuria; Vitamin D

Indexed keywords

ALBUMIN; CALCITRIOL; DOXORUBICIN; HEPARANASE; MESSENGER RNA; VITAMIN D; VITAMIN D RECEPTOR; BETA GLUCURONIDASE; HEPARAN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; GLOMERULUS; IN VITRO STUDY; KNOCKOUT MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEINURIA; RAT; RECEPTOR BINDING; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; WISTAR RAT;

ANIMALS; CALCITRIOL; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLUCURONIDASE; HEPARITIN SULFATE; MICE; MICE, KNOCKOUT; PODOCYTES; PROTEINURIA; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84956680116     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4593     Document Type: Article

References (44)

1. van den Born J, van den Heuvel LP, Bakker MA, et al., Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993; 43: 454-463.
2. Garsen M, Rops AL, Rabelink TJ, et al., The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant 2014; 29: 49-55.
3. van den Hoven MJ, Rops AL, Vlodavsky I, et al., Heparanase in glomerular diseases. Kidney Int 2007; 72: 543-548.
4. van den Hoven MJ, Rops AL, Bakker MA, et al., Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70: 2100-2108.
5. Smith RJ, Alexander J, Barlow PN, et al., New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456.
6. Kramer A, van den Hoven M, Rops A, et al., Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006; 17: 2513-2520.
7. Levidiotis V, Freeman C, Punler M, et al., A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 2004; 15: 2882-2892.
8. Levidiotis V, Freeman C, Tikellis C, et al., Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 2005; 10: 167-173.
9. Gil N, Goldberg R, Neuman T, et al., Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61: 208-216.
10. 3: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011; 25: 543-559.
11. Levin A, Bakris GL, Molitch M, et al., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
12. de Borst MH, Hajhosseiny R, Tamez H, et al., Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013; 24: 1863-1871.
13. Agarwal R, Acharya M, Tian J, et al., Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
14. Krairittichai U, Mahannopkul R, Bunnag S,. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai 2012; 95 (Suppl 3): S41-S47.
15. de Zeeuw D, Agarwal R, Amdahl M, et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
16. Fishbane S, Chittineni H, Packman M, et al., Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-652.
17. Liu LJ, Lv JC, Shi SF, et al., Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2012; 59: 67-74.
18. Thadhani R, Appelbaum E, Pritchett Y, et al., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. J Am Med Assoc 2012; 307: 674-684.
19. Kuhlmann A, Haas CS, Gross ML, et al., 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
20. Zou MS, Yu J, Nie GM, et al., 1,25-Dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int J Med Sci 2010; 7: 290-299.
21. Sonneveld R, Ferre S, Hoenderop JG, et al., Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease. Am J Pathol 2013; 182: 1196-1204.
22. 3-1α-hydroxylase knockout mice. FASEB J 2002; 16: 1398-1406.
23. Rops AL, Gotte M, Baselmans MH, et al., Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 2007; 72: 1204-1215.
24. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, et al., Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 1998; 273: 12960-12966.
25. Rops AL, van der Vlag J, Jacobs CW, et al., Isolation and characterization of conditionally immortalized mouse glomerular endothelial cell lines. Kidney Int 2004; 66: 2193-2201.
26. Mundel P, Reiser J, Zuniga Mejia Borja A, et al., Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
27. Jiang P, Kumar A, Parrillo JE, et al., Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 2002; 277: 8989-8998.
28. Malstrom K, Stange G, Murer H,. Identification of proximal tubular transport functions in the established kidney cell line, OK. Biochim Biophys Acta 1987; 902: 269-277.
29. van den Hoven MJ, Waanders F, Rops AL, et al., Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009; 24: 2637-2645.
30. Silver J, Naveh-Many T, Mayer H, et al., Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301.
31. Silver J, Russell J, Sherwood LM,. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 1985; 82: 4270-4273.
32. 3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
33. Assady S, Alter J, Axelman E, et al. Nephroprotective effect of heparanase in experimental nephrotic syndrome. PloS One 2015; 10: e0119610.
34. van den Hoven MJ, Wijnhoven TJ, Li JP, et al., Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 2008; 73: 278-287.
35. Zetser A, Bashenko Y, Edovitsky E, et al., Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66: 1455-1463.
36. Doi K, Noiri E, Fujita T,. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol 2010; 8: 122-128.
37. Sun YB, Qu X, Zhang X, et al., Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy. PloS One 2013; 8: e55027.
38. Moller CC, Wei C, Altintas MM, et al., Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18: 29-36.
39. Kuo YT, Kuo CH, Lam KP, et al., Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes. J Food Sci 2010; 75: H200-H204.
40. Tan X, Wen X, Liu Y,. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008; 19: 1741-1752.
41. Rops AL, van den Hoven MJ, Baselmans MM, et al., Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking. Kidney Int 2008; 73: 52-62.
42. Lerner I, Hermano E, Zcharia E, et al., Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011; 121: 1709-1721.
43. Jeansson M, Bjorck K, Tenstad O, et al., Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol 2009; 20: 114-122.
44. Wang Y, Borchert ML, Deluca HF,. Identification of the vitamin D receptor in various cells of the mouse kidney. Kidney Int 2012; 81: 993-1001.